Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3612 - Prognostic Nutritional Index (PNI) for cost effective utilisation of newer, expensive radiation technology for palliative treatment of all cancer patients with limited life expectancy.


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  End-of-life Care;  Surgical Oncology;  Radiation Oncology


Santhanam Sundar


Annals of Oncology (2017) 28 (suppl_5): v497-v501. 10.1093/annonc/mdx382


S. Sundar, J. Price, T. Wolfe, D. Thurairasa, E. Shawcroft

Author affiliations

  • Dept Of Oncology, Nottingham University Hospitals NHS Trust-City Hospital Campus, NG5 1PB - Nottingham/GB


Abstract 3612


Novel, complex, resource intensive, radiation technology is increasingly used for palliative therapy even though they are not cost effective in poor prognosis pts. (Kim IJROBP 2015;556). Since nearly half of all radiotherapy (RT) activity is palliative (Hoskin Cl Onc 2013;531), objective, validated prognostic tools are urgently needed to guide cost effective utilisation of RT. As advanced cancer is associated with poor nutritional status and immune dysfunction, we assessed prognostic role of PNI-which is based on serum albumin & peripheral blood lymphocytes.


Mortality of 233 unselected cancer pts treated over a 3 month at Nottingham was assessed. All tumour sites & histology were included. Overall Median age 68 yrs. Sites of RT field: Chest=29% Vertebrae=26% Pelvis=20% Brain=12% Limbs=6% Abd=3% Miscell=3%. 95% completed RT as planned. 93% had stage 4 cancer. PNI available for 131 pts. Majority not suitable for systemic therapy following palliative RT; only 15% and 28% had further hormones and chemo respectively.


Overall Median survival was 5.82 months; 38% died within 90 days of completing RT; Pts with low PNI (


For terminally ill cancer patients, who are not fit for further systemic therapy and whose PNI is 

Clinical trial identification

Legal entity responsible for the study

S Sundar




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.